Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are an important breakthrough in treating dyslipidemia since they lessen the degradation of LDL receptors, allowing for significant drops in LDL-C levels [10]. This evidence concerns the gene PCSK9 and metabolic syndrome.